Blood-brain barrier Part III: Therapeutic approaches to cross the blood-brain barrier and target the brain;Barrière hématoencéphalique Partie III : approche thérapeutique pour franchir la barrière hématoencéphalique

Revue Neurologique

Volumn 166, Issue 3, 2010, Pages 284-288

  Weiss, N ^a,b   Miller, F ^a   Cazaubon, S ^a   Couraud, P O ^a  

^a INSTITUT COCHIN   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Blood brain barrier; Drug delivery; Drug targeting; Receptors; Transporters

Indexed keywords

ABC TRANSPORTER; VIRUS VECTOR; XENOBIOTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN; DRUG ADMINISTRATION ROUTE; DRUG TARGETING; DRUG TRANSPORT; EFFUSION; ENDOTHELIUM CELL; HUMAN; MEMBRANE PERMEABILITY; NONHUMAN; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 77649232029     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2009.06.005     Document Type: Review

References (44)

1. Alexandrov A.V., Mikulik R., Ribo M., et al. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. Stroke 39 (2008) 1464-1469
2. Alonso M.M., Gomez-Manzano C., Bekele B.N., Yung W.K., and Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 67 (2007) 11499-11504
3. Begley D.J. ABC transporters and the blood-brain barrier. Curr Pharm Des 10 (2004) 1295-1312
4. Bickel U., Yoshikawa T., and Pardridge W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 46 (2001) 247-279
5. Cerletti A., Drewe J., Fricker G., Eberle A.N., and Huwyler J. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target 8 (2000) 435-446
6. Clinckers R., Smolders I., Meurs A., Ebinger G., and Michotte Y. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther 314 (2005) 725-731
7. de Boer A.G., van der Sandt I.C., and Gaillard P.J. The role of drug transporters at the blood-brain barrier. Ann Rev Pharmacol Toxicol 43 (2003) 629-656
8. de Lange E.C. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 56 (2004) 1793-1809
9. Dodge J.C., Clarke J., Song A., et al. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad Sci U S A 102 (2005) 17822-17827
10. Dombrowski S.M., Desai S.Y., Marroni M., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42 (2001) 1501-1506
11. Fjord-Larsen L., Johansen J.L., Kusk P., et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 195 (2005) 49-60
12. Hynynen K., and Sun J. Trans-skull ultrasound therapy: the feasibility of using image-derived skull thickness information to correct the phase distortion. IEEE Trans Ultrason Ferroelectr Freq Control 46 (1999) 752-755
13. Jeang K.T., Xiao H., and Rich E.A. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 274 (1999) 28837-28840
14. Kim R.B., Fromm M.F., Wandel C., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101 (1998) 289-294
15. Kinoshita M., McDannold N., Jolesz F.A., and Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A 103 (2006) 11719-11723
16. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. The blood-brain barrier and brain drug delivery. J Nanosci Nanotechnol 6 (2006) 2712-2735
17. Kroll R.A., and Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42 (1998) 1083-1099 [discussion 1099-100]
18. Liebner S., Corada M., Bangsow T., et al. Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol 183 (2008) 409-417
19. Loscher W., and Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6 (2005) 591-602
20. Meairs S., and Alonso A. Ultrasound, microbubbles and the blood-brain barrier. Prog Biophys Mol Biol 93 (2007) 354-362
21. Minagar A., Ostanin D., Long A.C., et al. Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult Scler 9 (2003) 235-238
22. Muldoon L.L., Nilaver G., Kroll R.A., et al. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpes virus, and iron oxide particles to normal rat brain. Am J Pathol 147 (1995) 1840-1851
23. Nicholas M.K. Glioblastoma multiforme: evidence-based approach to therapy. Expert Rev Anticancer Ther 7 (2007) S23-S27 [Suppl.]
24. Pardridge W.M. Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev 36 (1999) 299-321
25. Pardridge W.M., Boado R.J., and Kang Y.S. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci U S A 92 (1995) 5592-5596
26. Pardridge W.M., Eisenberg J., and Yang J. Human blood-brain barrier transferrin receptor. Metabolism 36 (1987) 892-895
27. Perez F., Joliot A., Bloch-Gallego E., Zahraoui A., Triller A., and Prochiantz A. Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J Cell Sci 102 (1992) 717-722
28. Prados M.D., Schold S.J.S., Fine H.A., et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol 5 (2003) 96-103
29. Raymond J.J., Robertson D.M., and Dinsdale H.B. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Sci 13 (1986) 214-220
30. Rousselle C., Clair P., Lefauconnier J.M., Kaczorek M., Scherrmann J.M., and Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 57 (2000) 679-686
31. Sheikov N., McDannold N., Vykhodtseva N., Jolesz F., and Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol 30 (2004) 979-989
32. Sisodiya S.M., Lin W.R., Harding B.N., Squier M.V., and Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125 (2002) 22-31
33. Soppimath K.S., Kulkarni A.R., and Aminabhavi T.M. Chemically modified polyacrylamide-g-guar gum-based crosslinked anionic microgels as pH-sensitive drug delivery systems: preparation and characterization. J Control Release 75 3 (2001) 331-345
34. Steffens S., Tebbets J., Kramm C.M., Lindemann D., Flake A., and Sena-Esteves M. Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes. J Neurooncol 70 (2004) 281-288
35. Summers M.A., Moore J.L., and McAuley J.W. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38 (2004) 1631-1634
36. Thomas S.A. Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 10 (2004) 1313-1324
37. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2 (2005) 54-62
38. Vezzani A. Gene therapy in epilepsy. Epilepsy Curr 4 (2004) 87-90
39. Washington C.B., Wiltshire H.R., Man M., et al. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 28 (2000) 1058-1062
40. Wielinga P.R., van der Heijden I., Reid G., Beijnen J.H., Wijnholds J., and Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 278 (2003) 17664-17671
41. Weiss N, Miller F, Cazaubon S, Couraud PO. Part I: Biology of the blood-brain barrier. Rev Neurol (Paris) doi:10.1016/j.neurol.2009.03.004.
42. Wolburg H., and Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38 (2002) 323-337
43. Yang F.Y., Fu W.M., Yang R.S., Liou H.C., Kang K.H., and Lin W.L. Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption. Ultrasound Med Biol 33 (2007) 1421-1427
44. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2008) 178-201